<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>research on Shixiang Wang | 王诗翔</title>
    <link>/categories/research/</link>
    <description>Recent content in research on Shixiang Wang | 王诗翔</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 20 Jun 2019 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="/categories/research/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer</title>
      <link>/cn/research/apobec3b_signature/</link>
      <pubDate>Thu, 20 Jun 2019 00:00:00 +0000</pubDate>
      
      <guid>/cn/research/apobec3b_signature/</guid>
      <description>主要发现：APOBEC mutational signature 在 NSCLC 免疫治疗反应组内特异性富集。 摘要 Non-small cell lung cancer (NSCLC) is known to carry heavy mutation load. Besides smoking, cytidine deaminase APOBEC3B plays a key role in the mutation process of NSCLC. APOBEC3B is also reported to be upregulated and predicts bad prognosis in</description>
    </item>
    
    <item>
      <title>The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex</title>
      <link>/cn/research/tmb_diff_in_sex/</link>
      <pubDate>Thu, 20 Jun 2019 00:00:00 +0000</pubDate>
      
      <guid>/cn/research/tmb_diff_in_sex/</guid>
      <description>主要发现：NSCLC 中，TMB 对于免疫治疗反应的预测效果在不同的性别中有差异。 摘要 Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a fraction of patients show response to ICI, and there is an unmet need</description>
    </item>
    
  </channel>
</rss>